C

Curia

End-to-end drug development and manufacturing

Validation Specialist 2

Full-Time
No salary listed
Mid
Bachelor's, Master's
Albuquerque, NM, USA
In Person
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A Bachelor’s degree in Mechanical Engineering or a related technical field with three (3) years of experience as a validation engineer, which includes 1 year of experience with the following: resolving protocol exceptions and deviations; developing Standard Operating Procedures (SOPs), process workflows, and validation; managing validation activities to minimize impact on production schedules; and FDA regulations, ISO 9000-3, PIC/S guidelines for cGMP, and GAMP 4 and 5 based on the GAMP V-Model Framework, as well as EU GMP Annex 11 for computer systems compliance.
  • A Master’s Degree in Mechanical Engineering, or a related field, with one (1) year of experience as a validation engineer, which includes 1 year of experience with the following: resolving protocol exceptions and deviations; developing Standard Operating Procedures (SOPs), process workflows, and validation; managing validation activities to minimize impact on production schedules; and FDA regulations, ISO 9000-3, PIC/S guidelines for cGMP, and GAMP 4 and 5 based on the GAMP V-Model Framework, as well as EU GMP Annex 11 for computer systems compliance.
Responsibilities
  • Develops, executes, and reviews validation protocols, including computer system validation, manufacturing equipment qualification, packaging equipment validation, and lyophilizer qualification;
  • Authors validation master plans and ensures compliance with regulatory and industry standards;
  • Conducts and oversees validation testing, analyzing data to assess the accuracy, reliability, and compliance of equipment, systems, instruments, and procedures. Prepares and reviews final reports, recommending adjustments or corrective actions as needed;
  • Collaborates with cross-functional teams to coordinate validation activities, ensuring timely completion with minimal impact on production schedules;
  • Provides technical guidance on new equipment, system modifications, and validation best practices;
  • Supports regulatory compliance by developing and refining validation procedures, recommending policy improvements, and ensuring adherence to FDA, cGMP, GAMP, and EU GMP Annex 11 requirements;
  • Engages with external vendors and consultants as needed for validation projects;
  • Provides technical training and support to personnel on validation processes and regulatory expectations;
  • Performs additional duties as assigned by management, including participation in special projects and continuous improvement initiatives;
  • Read/interpret SOPs to ensure compliance and maintain up-to-date trainings.

About the company

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.